These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 33190294)

  • 1. Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
    Machnicki MM; Górniak P; Pępek M; Szymczyk A; Iskierka-Jażdżewska E; Steckiewicz P; Bluszcz A; Rydzanicz M; Hus M; Płoski R; Makuch-Łasica H; Nowak G; Juszczyński P; Jamroziak K; Stokłosa T; Puła B
    Eur J Haematol; 2021 Mar; 106(3):320-326. PubMed ID: 33190294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
    Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V
    Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543
    [No Abstract]   [Full Text] [Related]  

  • 3. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening and monitoring of the BTK
    Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
    Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
    Molica S; Baumann T; Giannarelli D
    Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
    [No Abstract]   [Full Text] [Related]  

  • 6. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
    Molica S; Giannarelli D; Baumann T; Montserrat E
    Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
    Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
    Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
    Lama TG; Kyung D; O'Brien S
    Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
    Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
    Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
    Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
    Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
    Gángó A; Alpár D; Galik B; Marosvári D; Kiss R; Fésüs V; Aczél D; Eyüpoglu E; Nagy N; Nagy Á; Krizsán S; Reiniger L; Farkas P; Kozma A; Ádám E; Tasnády S; Réti M; Matolcsy A; Gyenesei A; Mátrai Z; Bödör C
    Int J Cancer; 2020 Jan; 146(1):85-93. PubMed ID: 31180577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
    JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
    Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
    Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.
    Woyach JA; Jones D; Jurczak W; Robak T; Illés Á; Kater AP; Ghia P; Byrd JC; Seymour JF; Long S; Mohamed N; Benrashid S; Lai TH; De Jesus G; Lai R; de Bruin G; Rule S; Munugalavadla V
    Blood; 2024 Sep; 144(10):1061-1068. PubMed ID: 38754046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.
    Aarup K; Rotbain EC; Enggaard L; Pedersen RS; Bergmann OJ; Thomsen RH; Frederiksen M; Frederiksen H; Nielsen T; Christiansen I; Andersen MA; Niemann CU
    Eur J Haematol; 2020 Nov; 105(5):646-654. PubMed ID: 32736410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
    Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
    Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
    Molica S; Gianfelici V; Levato L
    Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
    [No Abstract]   [Full Text] [Related]  

  • 19. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.
    Timofeeva N; Gandhi V
    Blood Cancer J; 2021 Apr; 11(4):79. PubMed ID: 33927183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
    Barrientos JC; Burger JA; Byrd JC; Hillmen P; Zhou C; Ninomoto J; James DF; Kipps TJ
    Leuk Lymphoma; 2019 Apr; 60(4):1000-1005. PubMed ID: 30277101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.